

Biostatistics

Other topics

Nuno Sepúlveda, 22.01.2024

Syllabus

1. General review

- a. What is Biostatistics?
- b. Population/Sample/Sample size
- c. Type of Data – quantitative and qualitative variables
- d. Common probability distributions
- e. Work example – Malaria in Tanzania

2. Applications in Medicine

- a. Construction and analysis of diagnostic tools – Binomial distribution, sensitivity, specificity, ROC curve, Rogal-Gladen estimator
- b. Estimation of treatment effects - generalized linear models
- c. Survival analysis - Kaplan-Meier curve, log-rank test, Cox's proportional hazards model

3. Applications in Genetics, Genomics, and other 'omics data

- a. Genetic association studies – Hardy-Weinberg test, homozygosity, minor allele frequencies, additive model, multiple testing correction
- b. Methylation association studies – M versus beta values, estimation of biological age
- c. Gene expression studies based on RNA-seq experiments – Tests based on Poisson and Negative-Binomial

4. Other Topics

- a. Estimation of Species diversity – Diversity indexes, Poisson mixture models
- b. Serological data analysis – Gaussian (skew-normal) mixture models
- c. Advanced sample size and power calculations

Serology




ANTIBODY
AGAINST
SARS-CoV-2

Serology, or **antibody**, testing checks a sample of a person's blood to look for antibodies against SARS-CoV-2, the virus that causes COVID-19. Antibodies usually become detectable in the blood **1-3 weeks** after someone is infected.



PERSON
INFECTED


1 - 3 WEEKS





Person has
detectable level
of antibodies.*

*Some people may take longer than 3 weeks to develop antibodies, and some people may not develop antibodies. It is currently unknown how long antibodies are detectable after infection.

Sero-epidemiological surveys





Antibody data are intrinsically quantitative





Rosado et al (2020). Serological signatures of SARS-CoV-2 infection: Implications for antibody-based diagnostics. medRxiv 2020.05.07.20093963.

Who are the seropositive individuals?



Rosado et al (2020). Serological signatures of SARS-CoV-2 infection: Implications for antibody-based diagnostics. medRxiv 2020.05.07.20093963.

How to determine the cut-off?



Approaches to determine the cutoff

```
graph TD; A[Approaches to determine the cutoff] --> B[Use of a known seronegative population]; A --> C[Use of data under analysis only]; B --> D[Pre-pandemic samples]; C --> E[Two-Gaussian mixture model]; D --> F[The 3-sigma rule]; E --> F;
```

Use of a known seronegative
population


Use of data under
analysis only

Pre-pandemic samples

Two-Gaussian mixture model

The 3-sigma rule

Approaches to determine the cutoff



The 3-sigma rule


$$\mu_{A^-} = E[X|A^-]$$

$$\sigma_{A^-} = \sqrt{\text{Var}[X|A^-]}$$


Seronegative, if $X_i \leq \mu_{A^-} + 3\sigma_{A^-}$

Seropositive, otherwise

The link to the Normal distribution



Quality control (Shewhart)



In practice (known seronegative population)

$$\mu_{A-} \rightarrow \bar{X}_{A-}$$

$$\sigma_{A-} \rightarrow s_{A-}$$

Seronegative, if $x_i \leq \bar{X}_{A-} + 3s_{A-}$

Seropositive, otherwise

Theoretical property of the 3-sigma

Cantelli-Chebyshev inequality

$$P[X \geq \mu + \lambda] \leq \frac{\sigma^2}{\sigma^2 + \lambda^2}, \text{ if } \lambda > 0$$

$$\mu = E[X] \quad \sigma^2 = \text{Var}[X] < \infty$$


Application to $\lambda = 3\sigma$

$$P[X \geq \mu_{A^-} + 3\sigma_{A^-}] \leq \frac{1}{10} \equiv 0.1$$



$$P[X \geq \mu_{A^-} + 3\sigma_{A^-}] > 0.9$$

Exercise: data_lecture_14_SARS_COV2_serology.csv




Apply the 3s-rule to pre-pandemic samples (status=negative) to calculate the cut-off for seropositivity of the anti-Spike-protein antibodies (Spike_IPP_IgG_MFI).

Calculate the proportion of these samples are above the threshold and check if this proportion agrees with the Cantelli-Chebyshev inequality.

Is the Normal distribution a reasonable distribution for the samples of SARS-CoV2-infected individual?

Apply this cutoff to calculate seroprevalence in SARS-CoV2-infected individual (status=positive).

Approaches to determine the cutoff



Gaussian mixture models

$$f_X(x) = \sum_{i=1}^k \pi_i f_{N(\mu_i, \sigma_i)}(x) \quad \text{where } \sum_{i=1}^k \pi_i = 1$$

The most common model $\rightarrow k = 2$

$$f_X(x) = (1 - \pi) f_{N(\mu_{S^-}, \sigma_{S^-})}(x) + \pi f_{N(\mu_{S^+}, \sigma_{S^+})}(x)$$

Definition of $S^- \Rightarrow \mu_{S^-} < \mu_{S^+}$

Estimation of the model

EM (Expectation-Maximization) Algorithm

1. Start with initial estimates for the parameters
2. E-Step - calculate the probability of each individual belonging to a given subpopulation according to estimates at 1.
3. M-Step - re-estimate the parameters using these probabilities and repeat the E-step with these new estimates
4. Stop with the increment in the log-likelihood is below a given tolerance error.

Package mixtools

Estimation of the model

EM (Expectation-Maximization) Algorithm

1. Start with initial estimates for the parameters
2. E-Step - calculate the probability of each individual belonging to a given subpopulation according to estimates at 1.
3. M-Step - re-estimate the parameters using these probabilities and repeat the E-step with these new estimates
4. Stop with the increment in the log-likelihood is below a given tolerance error.


Calculate the cutoff for seropositivity according to $\hat{\mu}_{S-}$ and $\hat{\sigma}_{S-}$

Package mixtools

Exercise: data_lecture_14_SARS_COV2_serology.csv

Articles

Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study




Jason Rosado, Stéphane Pelleau, Charlotte Cockram, Sarah Hélène Merklings, Narimane Nekkab, Caroline Demeret, Annalisa Meola, Solen Kerneis, Benjamin Terrier, Samira Fafi-Kremer, Jerome de Seze, Timothée Bruel, François Dejjardin, Stéphane Petres, Rhea Longley, Arnaud Fontanet, Marija Backovic, Ivo Mueller, Michael T White

Use the normalmixEM from the mixtools package to estimate a two-Gaussian mixture model to the data of anti-Spike-protein antibodies (Spike_IPP_IgG_MFI) from the SARS-CoV2-infected individual (status=positive).

Apply the 3s-rule to calculate the respective cut-off for seropositivity of the anti-Spike-protein antibodies (Spike_IPP_IgG_MFI).

Apply this cutoff to estimate the seroprevalence in these individuals.